Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of Durvalumab (MEDI4736) Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients (Dolphin study: WJOG11619L Investigator-Initiated Clinical Trial)

Next Previous
Trial Profile

Phase II study of Durvalumab (MEDI4736) Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients (Dolphin study: WJOG11619L Investigator-Initiated Clinical Trial)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Dolphin study; WJOG11619L

Most Recent Events

  • 09 Aug 2022 Primary endpoint progression free survival rate at 12 months has been met according to results presented at the 2022 World Conference on Lung Cancer
  • 09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer
  • 17 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top